RichardChaceMD
Ophthalmology • Portsmouth, NHCataract Related, Retinal Disease
Eyesight Ophthalmic Services Clear Advantage
Dr. Chace is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
155 Borthwick Ave
Ste 200
Portsmouth, NH 03801Phone+1 603-436-1773Fax+1 603-427-0655
Summary
- Dr. Richard Chace is an ophthalmologist in Portsmouth, NH and is affiliated with multiple hospitals in the area, including Exeter Hospital, Frisbie Memorial Hospital, Portsmouth Regional Hospital, and Wentworth-Douglass Hospital. He received his medical degree from Warren Alpert Medical School of Brown University and has been in practice 38 years. He specializes in cataract related and retinal disease and is experienced in cataracts, cataract surgery, glaucoma, vitreoretinal disease, and medical retina.
Education & Training
Tufts Medical CenterResidency, Ophthalmology, 1980 - 1983
Armed Forces Institute of PathologyNo degree, Opthalmic Pathology Course, 1982
Newton-Wellesley HospitalInternship, Internal Medicine, 1979 - 1980- Colby CollegeNo degree, Lancaster Course in Opthalmology, 1980
The Warren Alpert Medical School of Brown UniversityClass of 1979- Massachusetts Institute of TechnologyB.S., 1974
Certifications & Licensure
NH State Medical License 1983 - 2025- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Clinical Trials
- Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema Start of enrollment: 2007 Sep 01
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) Start of enrollment: 2007 Aug 01
- Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsCombination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II r...Ron P. Gallemore, Josh Wallsh, Henry L Hudson, Allen C. Ho, Richard Chace
Clinical Ophthalmology. 2017-01-24 - 13 citationsA Half Century of Burn Epidemiology and Burn Care in a Rural StateLaura L. Blaisdell, Reeve Chace, Lee D. Hallagan, David E. Clark
Journal of Burn Care & Research. 2012-05-01 - 9 citationsRetinal artery occlusion due to moyamoya disease.R Chace, T R Hedges rd
Journal of Clinical Neuro-Ophthalmology. 1984-03-01
Journal Articles
- Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degenration results of a phase II ran...Gallemore RP, Wallsh J, Hudson HL, Ho AC, Chace R, Pearlman J, Clin Opthalmol, 1/24/2017
- Sustained delivery fluocinolone acetonide vitreous implants, long term benefits in patients with chronic diabetic macular edemaCunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K, Chace R; FAME Study ..., Ophthalmology, 1/1/2014
Press Mentions
Effect of Initial Management with Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityMay 1st, 2019
External Links
- Eyesighthttp://www.eyesightnh.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
